Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


09.05.2022

3 Ann Intern Med
2 BMJ
2 Clin Infect Dis
1 J Infect Dis
3 JAMA
1 Lancet
2 MMWR Morb Mortal Wkly Rep
5 N Engl J Med
1 Pediatrics
1 PLoS Biol
1 PLoS Med
8 PLoS One
2 Proc Natl Acad Sci U S A
14 Vaccine
1 Virus Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. KRYCHTIUK KA, Newby LK
    Moderna COVID-19 vaccine was linked to myocarditis or myopericarditis at 28 d (4.2 events/100 000 persons).
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0021.
    PubMed         Abstract available

  2. GRANWEHR BP
    In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at >/=7 d after the second dose.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0028.
    PubMed         Abstract available

  3. ZAHRADKA I, Petr V, Modos I, Magicova M, et al
    Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients : A Registry-Based Report.
    Ann Intern Med. 2022 May 3. doi: 10.7326/M21-2973.
    PubMed         Abstract available


    BMJ

  4. MAHASE E
    Hepatitis: Ukrainian refugees should be offered vaccines and free treatment, says WHO.
    BMJ. 2022;377:o1132.
    PubMed        

  5. USTIANOWSKI A
    Why covid vaccine studies are still needed.
    BMJ. 2022;377:o1135.
    PubMed        


    Clin Infect Dis

  6. DOWLING DJ, Levy O
    A Precision Adjuvant Approach to Enhance SARS-CoV-2 Vaccines Optimized for Immunologically Distinct Vulnerable Populations.
    Clin Infect Dis. 2022 May 4. pii: 6580093. doi: 10.1093.
    PubMed         Abstract available

  7. BUTT AA, Talisa VB, Shaikh OS, Omer SB, et al
    Relative Vaccine Effectiveness of a SARS-CoV-2 mRNA Vaccine Booster Dose Against the Omicron Variant.
    Clin Infect Dis. 2022 May 3. pii: 6577096. doi: 10.1093.
    PubMed         Abstract available


    J Infect Dis

  8. KURAHASHI Y, Furukawa K, Sutandhio S, Tjan LH, et al
    Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.
    J Infect Dis. 2022 May 5. pii: 6580685. doi: 10.1093.
    PubMed         Abstract available


    JAMA

  9. SLOMSKI A
    Studies Examine Risk of Hearing Loss After COVID-19 Vaccination.
    JAMA. 2022;327:1641.
    PubMed        

  10. MARKS P, Woodcock J, Califf R
    COVID-19 Vaccination-Becoming Part of the New Normal.
    JAMA. 2022 May 2. pii: 2792030. doi: 10.1001/jama.2022.7469.
    PubMed        

  11. NISSEN SE, Wolski K, Balog C, Swerdlow DI, et al
    Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
    JAMA. 2022 Apr 3. pii: 2790912. doi: 10.1001/jama.2022.5050.
    PubMed         Abstract available


    Lancet

  12. ADEPOJU P
    Africa CDC warns COVID-19 vaccine production could cease.
    Lancet. 2022;399:1683.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  13. RAO AK, Briggs D, Moore SM, Whitehill F, et al
    Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:619-627.
    PubMed         Abstract available

  14. PRASAD N, Derado G, Nanduri SA, Reses HE, et al
    Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:633-637.
    PubMed         Abstract available


    N Engl J Med

  15. NOHYNEK H, Wilder-Smith A
    Does the World Still Need New Covid-19 Vaccines?
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMe2204695.
    PubMed        

  16. DAI L, Gao L, Tao L, Hadinegoro SR, et al
    Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2202261.
    PubMed         Abstract available

  17. GRAY G, Collie S, Goga A, Garrett N, et al
    Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMc2202061.
    PubMed        

  18. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Need New Covid-19 Vaccines?
    N Engl J Med. 2022;386:e52.
    PubMed        

  19. HAGER KJ, Perez Marc G, Gobeil P, Diaz RS, et al
    Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2201300.
    PubMed         Abstract available


    Pediatrics

  20. ROSS LF
    State Versus Adolescent Override for Parental Refusals to Vaccinate Against COVID-19.
    Pediatrics. 2022;149.
    PubMed        


    PLoS Biol

  21. ZHU DY, Gorman MJ, Yuan D, Yu J, et al
    Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.
    PLoS Biol. 2022;20:e3001609.
    PubMed         Abstract available


    PLoS Med

  22. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    Correction: COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2022;19:e1003990.
    PubMed         Abstract available


    PLoS One

  23. HONSKUS M, Okonji Z, Musilek M, Krizova P, et al
    Whole genome sequencing of Neisseria meningitidis Y isolates collected in the Czech Republic in 1993-2018.
    PLoS One. 2022;17:e0265066.
    PubMed         Abstract available

  24. STOTO MA, Schlageter S, Kraemer JD
    COVID-19 mortality in the United States: It's been two Americas from the start.
    PLoS One. 2022;17:e0265053.
    PubMed         Abstract available

  25. FLOREA A, Sy LS, Luo Y, Qian L, et al
    Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study.
    PLoS One. 2022;17:e0267824.
    PubMed         Abstract available

  26. BICHER M, Rippinger C, Zechmeister M, Jahn B, et al
    An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply.
    PLoS One. 2022;17:e0265957.
    PubMed         Abstract available

  27. DONG L, Bogart LM, Gandhi P, Aboagye JB, et al
    A qualitative study of COVID-19 vaccine intentions and mistrust in Black Americans: Recommendations for vaccine dissemination and uptake.
    PLoS One. 2022;17:e0268020.
    PubMed         Abstract available

  28. STOCKLI S, Spalti AK, Phillips J, Stoeckel F, et al
    Which vaccine attributes foster vaccine uptake? A cross-country conjoint experiment.
    PLoS One. 2022;17:e0266003.
    PubMed         Abstract available

  29. ASSI S, Arafat B, Abbas I, Evans K, et al
    Evaluation of portable near-infrared spectroscopy for authentication of mRNA based COVID-19 vaccines.
    PLoS One. 2022;17:e0267214.
    PubMed         Abstract available

  30. HONG H, Malfeld S, Smit S, Makhathini L, et al
    A retrospective 5-year review of rubella in South Africa prior to the introduction of a rubella-containing vaccine.
    PLoS One. 2022;17:e0265870.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  31. DUCH R, Robinson TS, Clarke PM, Roope LSJ, et al
    Reply to Spreco et al.: Perceived corruption and preferences for COVID-19 vaccine allocations.
    Proc Natl Acad Sci U S A. 2022;119:e2201847119.
    PubMed        

  32. SPRECO A, Schon T, Timpka T
    Corruption should be taken into account when considering COVID-19 vaccine allocation.
    Proc Natl Acad Sci U S A. 2022;119:e2122664119.
    PubMed        


    Vaccine

  33. KOULIDIATI JL, Kabore R, I Nebie E, Sidibe A, et al
    Timely completion of childhood vaccination and its predictors in Burkina Faso.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00497.
    PubMed         Abstract available

  34. TAMANG ST, Dorji T
    COVID-19 vaccinations in Bhutan - Mix-and-Match to Boosters: An experience.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00499.
    PubMed         Abstract available

  35. SINGH BK, Walker J, Paul P, Reddy S, et al
    De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00467.
    PubMed         Abstract available

  36. JAFFLIN K, Deml MJ, Schwendener CL, Kiener L, et al
    Parental and provider vaccine hesitancy and non-timely childhood vaccination in Switzerland.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00472.
    PubMed         Abstract available

  37. MARKOVITZ NH, Strome AL, Patel PK
    Commentary: "The vaccine Selfie" and its influence on COVID-19 vaccine acceptance.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00503.
    PubMed        

  38. LV H, Wang S, Liang Z, Yu W, et al
    Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00205.
    PubMed         Abstract available

  39. SALO H, Lehtonen T, Auranen K, Baum U, et al
    Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00495.
    PubMed         Abstract available

  40. MORO PL, Olson CK, Clark E, Marquez P, et al
    Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00447.
    PubMed         Abstract available

  41. TAMURA K, Chang B, Shimbashi R, Watanabe H, et al
    Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00502.
    PubMed         Abstract available

  42. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00463.
    PubMed         Abstract available

  43. TAMURA K, Kohnoe M, Takashino A, Kobayashi K, et al
    TAK - 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00518.
    PubMed         Abstract available

  44. GREYSON D, Carpiano RM, Bettinger JA
    Support for a vaccination documentation mandate in British Columbia, Canada.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00247.
    PubMed         Abstract available

  45. TOLL M, Li A
    Vaccine mandates on childcare entry without conscientious objection exemptions: A quasi-experimental panel study.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00461.
    PubMed         Abstract available

  46. DEMIR E, Dheir H, Safak S, Serra Artan A, et al
    Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00519.
    PubMed         Abstract available


    Virus Res

  47. ALMEIDA F, Santos LA, Trigueiro-Louro JM, RebelodeAndrade H, et al
    Optimization of A(H1N1)pdm09 vaccine seed viruses: the source of PB1 and HA vRNA as a major determinant for antigen yield.
    Virus Res. 2022 Apr 30:198795. doi: 10.1016/j.virusres.2022.198795.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: